Traditional Chinese medicine formula T33 inhibits the proliferation of human colorectal cancer cells by inducing autophagy.

Colorectal cancer (CRC) is a leading cause of cancer-related death globally. Although surgery is still the major method for CRC therapy, the adoption of alternative treatments, such as traditional Chinese medicine (TCM), for CRC treatment is increasing. Our previous study has indicated the anti-breast cancer activity of T33 (a TCM formula).

One-Pot CuI/DBU-Catalyzed Carboxylative Cyclization toward Oxazolidinones Using Recyclable Molecular Sieves as Efficient Promoters for Fixation of CO in Water Medium.

An efficient one-pot synthesis of oxazolidinones was developed through CuI/DBU/MS joint system-catalyzed carboxylative cyclization of arylacetylene, arylaldehyde, and arylamine in water medium under a 1 atm carbon dioxide (CO) atmosphere. The 4 Å molecular sieves (MSs) were added to improve CO capture and facilitate carboxylation to give the products in high yields. The CuI/DBU/MS system is robust and highly effective for the reactions with different substrates, and some target products were obtained in an excellent yield of ∼96%, with no side products in the final step.

In vitro and in vivo effects of traditional Chinese medicine formula T33 in human breast cancer cells.

Background: Breast cancer is the leading cause of cancer-related death in women worldwide. Although traditional Chinese medicine (TCM) is commonly used by patients with breast cancer, little is known about TCM prescriptions for breast cancer. This study investigated the effects of a new TCM formula, T33, comprising Radix Kansui, Rheum rhabarbarum, Paeonia lactiflora, Jiangbanxia, and Zhigancao on breast cancer cells in vitro and in vivo.